Related Experiment Video
Updated: May 12, 2026

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy
Published on: November 7, 2017
Uremic cardiomyopathy: an underdiagnosed disease
Eyad Alhaj1, Nehad Alhaj, Ifad Rahman
1Department of Cardiology, UMDNJ, New Jersey Medical School, Newark, NJ 07103, USA. Eyadalhaj@yahoo.com
Uremic cardiomyopathy, common in chronic kidney disease (CKD) and end-stage renal disease (ESRD), may be slowed by early hemodialysis. Kidney transplantation offers significant survival benefits and can reverse this condition.
Area of Science:
- Nephrology
- Cardiology
- Internal Medicine
Background:
- Uremic cardiomyopathy significantly increases morbidity and mortality in chronic kidney disease (CKD) and end-stage renal disease (ESRD) patients.
- Early intervention is crucial for managing this condition.
Purpose of the Study:
- To review the impact of hemodialysis and kidney transplantation on uremic cardiomyopathy.
- To explore potential future therapeutic targets.
Main Methods:
- Literature review of studies on hemodialysis (conventional and frequent) and kidney transplantation in CKD/ESRD patients.
- Analysis of data on uremic cardiomyopathy progression and reversal.
Main Results:
- Early hemodialysis may halt the progression of uremic cardiomyopathy.
- Frequent hemodialysis shows potential advantages over conventional hemodialysis.
- Kidney transplantation can reverse uremic cardiomyopathy and improve survival.
Conclusions:
- Hemodialysis and kidney transplantation are key interventions for uremic cardiomyopathy in CKD/ESRD.
- Future therapies should focus on cellular mechanisms to reduce the burden of uremic cardiomyopathy.
Related Concept Videos
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy
Myocarditis II: Clinical Features and Diagnostic Tests
Cardiomyopathy V: Interprofessional Care
